Skip to main content
Fig. 3 | BMC Urology

Fig. 3

From: Combination therapy only shows short-term superiority over monotherapy on ureteral stent-related symptoms – outcome from a randomized controlled trial

Fig. 3

Solifenacin, tamsulosin and combination therapy all released SRSs comparing to the control group (p = 0.004 vs 0.026 vs <0.001). Combination therapy could release the SRSs much faster than solifenacin (p = 0.016) or tamsulosin (0.002) in the first 4 days. No significant differences showed up between combination and solifenacin (p = 0.842) or tamsulosin (p = 0.774) alone from day5 to day14. Solifenacin and tamsulosin showed comparable effect throughout the whole follow up (p = 0.582)

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us